Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome

Trial Profile

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs Patidegib (Primary)
  • Indications Basal cell nevus syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms BCCs
  • Sponsors PellePharm
  • Most Recent Events

    • 20 Nov 2018 According to a LEO Pharma media release, this trial is expected to begin recruitment in early 2019.
    • 20 Nov 2018 According to a LEO Pharma media release, LEO Pharma has initially committed $70 million comprised of equity financing and financial R&D support to fund this trial.
    • 16 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 5 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top